Diplomat to Dispense Multiple Myeloma Combination Drug DARZALEX®
FLINT, Mich. – Dec. 1, 2016 – The nation’s largest independent specialty pharmacy will have access to dispense DARZALEX® (daratumumab) to treat patients who have multiple myeloma.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it will be dispensing DARZALEX® (daratumumab) in combination with REVLIMID® (lenalidomide) and dexamethasone or with VELCADE® (bortezomib) and dexamethasone.
DARZALEX was recently approved by the Food and Drug Administration to treat patients with multiple myeloma who have received at least one other treatment.
The FDA had previously approved DARZALEX to treat patients who have received three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or those who are resistant to both a PI and an immunomodulatory agent.
To learn more about Diplomat’s oncology program, visit diplomat.is/areas-of-excellence/oncology.
DARZALEX is a monoclonal antibody that works with the immune system. It attaches to a protein called CD38, on the surface of many myeloma cells. Once DARZALEX attaches to the CD38 protein, it helps the immune system find and kill myeloma cells. DARZALEX is the first anti-CD38 in the world approved for humans.
“At Diplomat, we are focused on providing excellent care to every single patient,” said Paul Urick, Diplomat’s president. “With DARZALEX, we are able to offer a treatment to our multiple myeloma patients who have tried at least one other therapy. Along the way, our oncology team of pharmacists, nurses, and care coordinators works hard to provide a consistent high level of care to support them at all times as they grapple with multiple myeloma.”
Multiple myeloma is a hematological (blood) cancer in which malignant plasma cells form in the bone marrow, producing abnormal proteins. Because plasma cells circulate widely in the body, they can affect many bones and result in compression fractures, lytic bone lesions, and related pain. According to the American Cancer Society, about 30,330 Americans will be diagnosed with multiple myeloma in 2016.
DARZALEX is manufactured by Janssen Biotech, Inc. For full prescribing information on DARZALEX, click here.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit diplomat.is.
Kali Lucas, Public Relations Specialist
810.768.9580 | email@example.com
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | firstname.lastname@example.org
@DiplomatRx@JNJNews treatment Zytiga significantly cut the death risk for ... prostate cancer patients by 38% https://t.co/6Ga1okf4Ye @ASCO #ASCO173 days ago
@sloan_ketteringRT @sloan_kettering: Your immune system provides one of the best defenses against cancer. But sometimes it needs a little help. More about…6 days ago
@DiplomatRxThank you to @corpmagazine for recognizing Diplomat as a 2017 Michigan Economic Bright Spot awardee!2 weeks ago
@DiplomatRxFriend and Patient Advocate, Brenda Williams Hawkes was featured in @MyGoodDays Days this month!… https://t.co/TFGSoMecqO2 weeks ago
@DiplomatRxJeff Park Elected to Diplomat Board of Directors https://t.co/IMI1aRwNbm2 weeks ago